APA (7th ed.) Citation

Nash, P., Behrens, F., Orbai, A., Rathmann, S. S., Adams, D. H., Benichou, O., & Deodhar, A. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Nash, Peter, Frank Behrens, Ana-Maria Orbai, Suchitrita S. Rathmann, David H. Adams, Olivier Benichou, and Atul Deodhar. Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-modifying Antirheumatic Drugs (cDMARDs) in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors. BMJ Publishing Group.

MLA (9th ed.) Citation

Nash, Peter, et al. Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-modifying Antirheumatic Drugs (cDMARDs) in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors. BMJ Publishing Group.